KALA BIO has announced plans to introduce its first commercial AI product in approximately 14 days, leading to a remarkable surge in its stock price. The company is positioning itself within the burgeoning $180 billion AI-in-healthcare market, aspiring to be the ‘Palantir for biotech.’
Following the announcement, KALA BIO’s stock jumped by 69.68% during pre-market trading on Wednesday, adding to a 12.82% increase observed the previous day. Trading volume soared to over 51 million shares, a stark contrast to the three-month daily average of around 1.94 million shares.
The forthcoming platform, named Researgency.ai, is designed to deploy AI agents specifically aimed at enhancing workflows in the biotech and pharmaceutical sectors. KALA BIO’s leadership has expressed a clear ambition to replicate the success of industry leader Palantir, which boasts a market capitalisation exceeding $250 billion.
CEO Avi Minkowitz stated, “Our first agent ships in 14 days, and our team is fired up.” The company is collaborating with Younet’s AI engineering team to develop this inaugural custom agent, which is expected to be delivered by late March. Notably, the Researgency.ai platform is already operational and accessible to enterprise clients.
Functionality of the Researgency.ai Platform
The AI agents are engineered to manage time-intensive and critical tasks associated with drug development. These tasks encompass research monitoring, documentation of clinical trials, regulatory compliance, safety reporting, and preparations for commercial launch.
KALA BIO asserts that these agents will perform these functions more efficiently, at a lower cost, and with fewer errors compared to human workers. The agents are designed to operate within a secure environment that adheres to pharmaceutical-grade compliance standards.
Market analysts project that the global AI-in-healthcare sector will exceed $180 billion by 2030. Despite this optimistic outlook, KALA BIO’s current market capitalisation stands at approximately $8.3 million, with share prices trading at $0.29. It is important to note that the stock is down 47.21% year-to-date and has decreased by 95.78% over the past year, indicating that despite recent gains, it remains near historical lows.
Strategic Directions and Financial Considerations
KALA BIO is pursuing a dual strategy that incorporates both its biologics pipeline and its new AI initiative. The company’s biologics pipeline includes candidates that have received FDA Orphan Drug and Fast Track designations, which are built on its mesenchymal stem cell secretome platform.
The pivot towards AI comes amid significant financial challenges. KALA BIO’s current ratio is reported at 0.75, indicating that the company’s short-term liabilities exceed its liquid assets. Earlier this year, KALA resolved a debt dispute with Oxford Finance by making a $2 million payment against approximately $10.6 million in obligations stemming from a prior loan agreement.
Additionally, KALA BIO has recently terminated its relationship with Deloitte & Touche LLP, its auditor, although a successor has yet to be appointed.
Details regarding the pricing of the Researgency.ai platform, the specific workflow targeted by the first agent, and any existing client commitments remain undisclosed. KALA BIO has indicated that comprehensive information about the first AI agent, including its targeted workflow and performance metrics, will be made available following its launch.